Over the last decade, revolutionary advances in our understanding of the molecular basis of cancer have gone hand in hand with extraordinary advances in our ability to identify and design novel inhibitors of target proteins. This sets the stage for a dramatic increase in the development of novel, highly effective and specific therapeutic approaches for cancer treatment.
However, the frontier of knowledge about cancer may be limited by the current biomedical models. Therefore, development of a new model more appropriate for pre-clinical studies is imperative for the testing of many new therapies including new drugs, imaging technologies and hypothermia, radiation and photodynamic therapy. In addition, studies of drug delivery and bimodal therapies require a model such as the pig which is more closely aligned with the human genome, physiology and anatomy. The parallels in cancer biology between pigs and humans are even conserved at the molecular level. In both species telomerase and other genes are suppressed in a number of tissues but reactivated during cancer. Specific mutations common to human cancers are becoming the target of inducible porcine cancer studies, these may overcome some of the limitations in modeling human cancer. are a main challenge for geneticists and molecular oncologists.
Topics will include but be not limited to:
· · Defining the need for new cancer models;
· A new model more appropriate for pre-clinical studies;
· Spontaneous cancer in pigs.
· Parallels in cancer biology between mice, pigs and humans;
· New model for new therapies including new drugs, imaging technologies and hypothermia, radiation and photodynamic therapy.
· How has the swine genomic sequence influenced cancer research;
· Porcine embryonic stem cells;
· Porcine induced pluripotent stem cells.
· Myelogenous leukemia in adult inbred miniature swine;
· Porcine in vivo lung cancer model;
· Chemotherapy in the pig model;
· A porcine model of familial adenomatous polyposis;
· Genetic induction of tumorigenesis in swine;
· Role of telomerase, p53, Kras and other oncogenes in pig cancer;
· Technological advances to generate transgenic pigs for cancer research;
· Efficacy of porcine models;
· Progress in reproductive biotechnology of swine;
· Targeted genome editing in pigs;
Over the last decade, revolutionary advances in our understanding of the molecular basis of cancer have gone hand in hand with extraordinary advances in our ability to identify and design novel inhibitors of target proteins. This sets the stage for a dramatic increase in the development of novel, highly effective and specific therapeutic approaches for cancer treatment.
However, the frontier of knowledge about cancer may be limited by the current biomedical models. Therefore, development of a new model more appropriate for pre-clinical studies is imperative for the testing of many new therapies including new drugs, imaging technologies and hypothermia, radiation and photodynamic therapy. In addition, studies of drug delivery and bimodal therapies require a model such as the pig which is more closely aligned with the human genome, physiology and anatomy. The parallels in cancer biology between pigs and humans are even conserved at the molecular level. In both species telomerase and other genes are suppressed in a number of tissues but reactivated during cancer. Specific mutations common to human cancers are becoming the target of inducible porcine cancer studies, these may overcome some of the limitations in modeling human cancer. are a main challenge for geneticists and molecular oncologists.
Topics will include but be not limited to:
· · Defining the need for new cancer models;
· A new model more appropriate for pre-clinical studies;
· Spontaneous cancer in pigs.
· Parallels in cancer biology between mice, pigs and humans;
· New model for new therapies including new drugs, imaging technologies and hypothermia, radiation and photodynamic therapy.
· How has the swine genomic sequence influenced cancer research;
· Porcine embryonic stem cells;
· Porcine induced pluripotent stem cells.
· Myelogenous leukemia in adult inbred miniature swine;
· Porcine in vivo lung cancer model;
· Chemotherapy in the pig model;
· A porcine model of familial adenomatous polyposis;
· Genetic induction of tumorigenesis in swine;
· Role of telomerase, p53, Kras and other oncogenes in pig cancer;
· Technological advances to generate transgenic pigs for cancer research;
· Efficacy of porcine models;
· Progress in reproductive biotechnology of swine;
· Targeted genome editing in pigs;
